Sun Pharma receives FDA permission for generic AmBisome Liposome injection
AmBisome Liposome for injection had a market value of approximately $136 million as of October 2021.
Sun Pharma has received the Food and Drug Administration’s blessing for generic Amphotericin B Liposome for injection, 50 mg/vial single-dose vial.
The product is the generic of AmBisome Liposome for injection.
[Read more: Sun Pharma intros 2 generics]
Sun Pharma has been granted Competitive Generic Therapy designation and being the first approved generic, the product is eligible for 180 days of CGT exclusivity.
AmBisome Liposome for injection, 50mg/vial had a market value of approximately $136 million as of October 2021, according to IQVIA.
[Read more: Sun Pharma intros generic Concerta]